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Abstract
Background: Geriatric Patients Living with HIV/AIDS (GEPPO) is a new prospective observational multicentre cohort
consisting of all the HIV-positive geriatric patients being treated at 10 clinics in Italy, and HIV-negative controls
attending a single geriatric clinic.
The aim of this analysis of the GEPPO cohort was to compare prevalence and risk factors of individual non-
communicable diseases (NCD), multi-morbidity (MM) and polypharmacy (PP) amongst HIV positive and HIV negative
controls at enrolment into the GEPPO cohort.
Methods: This cross-sectional study was conducted between June 2015 and May 2016. The duration of HIV infection
was subdivided into three intervals: < 10, 10–20 and > 20 years. The NCD diagnoses were based on guidelines defined
criteria, including cardiovascular disease, hypertension, type 2 diabetes, chronic kidney disease, dyslipidaemia, chronic
obstructive pulmonary disease. MM was classified as the presence of two or more co-morbidities. The medications
prescribed for the treatment of comorbidities were collected in both HIV positive and HIV negative group from patient
files and were categorized using the Anatomical Therapeutic Chemical (ATC) classification. PP was defined as the presence
of five or more drug components other than anti-retroviral agents.
Results: The study involved a total of 1573 patient: 1258 HIV positive and 315 HIV negative). The prevalence of individual
comorbidities was similar in the two groups with the exception of dyslipidaemia, which was more frequent in the
HIV-positive patients (p < 0.01). When the HIV-positive group was stratified based on the duration of HIV infection,
most of the co-morbidities were significantly more frequent than in control patients, except for hypertension and
cardiovascular disease, while COPD was more prevalent in the control group. MM and PP were both more prevalent
in the HIV-positive group, respectively 64% and 37%.
Conclusions: MM and PP burden in geriatric HIV positive patients are related to longer duration of HIV-infection rather
than older age per se.
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Background
Aging populations are about to become the next global
challenge for global public health. Advances in medicine
and socio-economic development have substantially re-
duced morbidity and mortality due to infectious condi-
tions and, to some extent, non-communicable diseases
(NCD) [1]. Moreover, the longer survival of people with
chronic conditions explains the increasing proportion of
people living with NCDs. The co-existence of two or
more NCDs is usually defined as multi-morbidity (MM)
[2, 3]. Empirical studies based on surveys and general
practice records show that MM is highly prevalent
among older adults [4], and is associated with more
medication prescriptions (polypharmacy, PP), the greater
use of healthcare services, greater disability and mortal-
ity, and a poorer health-related quality of life [5–7]. The
demographic shift has led gerontologists to recognise
the different conditions that people experience during
the years known as geriatric age, above 65 years. Fur-
thermore, it has brought with it the widely used sub-
grouping into the youngest-old (65–74 years), the old
(75–84 years), and the oldest-old (≥ 85 years) [8].
In the relatively new context of global aging, Human
Immunodeficiency Virus (HIV) infection is less an ex-
ception than a paradigm. The increasing age of people
living with HIV (PLWH) is the net result of increased
survival due to effective antiretroviral therapy (ART) and
older age at the time the infection is acquired [9]. A few
studies have assessed the clinical presentation of aging
HIV patients, particularly the proportion of age-related
NCD affecting those aged > 50 years [10–14].
Two European cohorts (POPPY and AgeHIV) identi-
fied well-matched HIV-negative subjects. This allowed
to study the impact of HIV specific risk factors such as
ART exposure and toxicity, immune dysfunction or dys-
regulation, and chronic immune activation and inflam-
mation [14–19]. Unfortunately, median age of these
cohorts are below 50 years and none of these studies
have a significant proportion of subjects of appropriately
defined geriatric age.
The clinical characteristics of more than 400 patients
aged > 75 years in a large French database were de-
scribed at the 2016 Conference on Retroviruses and Op-
portunistic Infection (CROI, Boston, 22–25 February
2016). However, they acquired HIV infection at a late
age (the median age at the time of starting ART being
64.5 years, range 60–70) [20]. These data have not been
published so far. Therefore, the clinical presentation and
aging trajectory of geriatric patients aging with HIV in-
fection is still unknown.
Geriatric Patients Living with HIV/AIDS (GEPPO) is a
new prospective observational multicentre cohort in-
cluding consecutive HIV-positive geriatric patients in
care at 10 HIV clinics in Northern Central and Southern
Italy, and HIV-negative controls attending a single geri-
atric clinic.
The overall aims of the GEPPO study are to determine
the health status of HIV-positive patients aged ≥65 years
and its changes over time. A further aim is to investigate
the extent to which the geriatric care model applies to
HIV positive patients. Finally, it is intended to identify
the contemporary morbidity, mortality and disability fac-
tors affecting healthy life expectancy of geriatric HIV
positive patients.
In this analysis we compared prevalence and risk fac-
tors of individual non-communicable diseases, multi-
morbidity and polypharmacy amongst HIV positive and
HIV negative controls at enrolment into the GEPPO
cohort. Cross-sectional comparison was stratified by age
groups, namely: youngest old (65–75) and old (≥75 years).
Methods
This is a cross-sectional analysis of HIV positive and
HIV negative geriatric patients at the time of GEPPO
cohort entry between June 2015 and May 2016. The
patients were recruited at the time of routine follow up
visit at ten HIV clinics in Northern, Central and Southern
Italy with a geographical spread of 1000 Km, and were
stratified into two groups: the “youngest old” (65–74 years)
and the “old” (≥ 75 years). The inclusion criteria were age
of ≥65 years, treatment with ART for at least six months
and signed informed consent.
The HIV-negative subjects were selected from those
attending a single geriatric clinic located in the same
geographical area as the coordinating site (Modena).
This centre offers, general practitioners support in
screening NCDs in geriatric patients. The only inclusion
criterion was age ≥ 65 years. Given the easy access and
free of charge of any diagnostic procedure in geriatric
patients, this cohort is representative of the general
Italian population.
Ethics
Institutional review Board (IRB) approval was obtained
from the Research Ethics Committee of each centre par-
ticipating in the GEPPO cohort study. Both HIV positive
and HIV negative participants gave their written informed
consent, at the time of their initial visit.
Covariates
The demographic covariates and clinical outcomes of
the HIV positive and HIV negative subjects were charac-
terised and compared. They included: age, gender, BMI,
smoking status. Ex- and never-smokers were grouped
together and compared to current smokers. The vari-
ables considered in HIV positive patients included:
current and nadir CD4 cell counts, CD4/CD8 ratio,
plasma HIV RNA viral load (VL). The duration of HIV
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infection was calculated as the time between diagnosis
and the last visit, and was stratified into < 10, 10–20
and > 20 years. The duration of ART was calculated as
the time between the start of ART and the last visit.
Outcomes
The NCDs diagnoses were based on guidelines defined
criteria [21]. The cardiovascular disease (CVD) category
consisted of diagnoses of myocardial infarction, coronary
artery disease, peripheral vascular disease, stroke and
angina pectoris, as well as coronary artery bypass graft-
ing and angioplasty, based on records in patient files.
Hypertension (HTN) was defined as two consecutive
measurements of blood pressure > 140/90 mmHg or use
of antihypertensive drugs. Type 2 diabetes mellitus
(T2DM) was defined as fasting serum glucose levels
≥126 mg/dL or use of antidiabetic drugs. Chronic kidney
disease (CKD) was confirmed at an estimated glomerular
filtration rate (eGFR) of < 60 mL/min calculated using
Chronic Kidney Disease Epidemiology Collaboration
(CKD-Epi) equation mL/min/1.73 m2. Dyslipidaemia
(DLM) was defined in patients with fasting total choles-
terol levels > 200 mg/dL or triglyceride levels of > 150 mg/
dL or the current use of statins. Diagnosis of HTN, CKD
and DLM were confirmed in two consecutive measure-
ments. Chronic obstructive pulmonary disease (COPD)
was defined based on pulmonary function tests (spirom-
etry, diffusion capacity of carbon monoxide [DLCO])
demonstrating FEV1/forced vital capacity (FVC) ratios <
70%. MM was defined as the presence of two or more
NCDs [2, 3].
The medications prescribed for the treatment of NCDs
were collected from patient files in both HIV positive
and HIV negative groups and were categorized using the
Anatomical Therapeutic Chemical (ATC) classification
in which the drugs are divided into different groups
based on therapeutic indication [22]. The analysis con-
sidered the prevalence of the six most frequently pre-
scribed classes other than ART with particular regards
of cardiovascular active agents including statins, beta-
blocker, ACE-inhibitors, anti-hypertensives and acetyl-
salicylic acid (ASA) and psychoactive agents including
benzodiazepines (BDZ).
Polypharmacy was defined as the presence of five or
more drug components other than ART. The decision
not to include ART was due to the need to compare
HIV-positive and HIV-negative subjects.
Statistical analysis
In the participating Centres the study size of the
HIV-positive patients was represented by the whole of
HIV infected patients meeting inclusion criteria, who
presented at routine medical visits in the enrolment
period (year 2015).
Per protocol the two groups were matched for age
(±4 years) within male and female groups through a 4:1
ratio, using random selection. A reduced number of HIV
negative people were chosen with a view to the large
sample size of HIV patients.
Missing data on outcomes were indicated in the tables
as different denominators for parentage values.
The between-group comparisons were made using the
χ2 test for categorical variables, and the t test or Mann-
Whitney U-test for the normally and non-normally dis-
tributed continuous variables respectively.
The probability of MM and PP at each age was com-
pared in the HIV-negative controls and the HIV-positive
patients stratified as of the duration of HIV infection (<
10, 10–20 and > 20 years). These times were chosen for
two main reasons. Firstly they paralleled the tertile
distribution of this variable. Secondly, they identified the
subsets of subjects aging since the pre-ART, and the
early and the late-ART periods.
Multivariable logistic regression models were built to
predict MM and PP including the following as covariates:
age categories, gender, BMI, current smoke and duration
of HIV infection, using HIV negative as reference.
A second model was restricted to HIV patients in-
cluding HIV related variables such as: current CD4,
CD4 Nadir, CD4/CD8 ratio, HIV-1 VL undetectability
(< 40 copies/mL), and residual of ART duration after
adjustment for HIV infection duration.
Residual ART duration was calculated through univari-
ate linear regression between ART exposure and duration
of HIV infection. This was performed to avoid co-linearity
between these two variables.
Statistical analyses were performed using the “R” Soft-
ware, version 3·2.
Results
The study involved a total of 1573 patient (1258 HIV
positive and 315 HIV negative). The HIV-positive pa-
tients aged 65–74 and ≥ 75 respectively represented 3.8%
and 0.5% of the HIV-positive populations at the GEPPO
recruiting sites.
With regards to demographic and anthropometric
variables, mean age was 72 (SD = 4.27) years for men
and 71 (SD = 3.94) years for women. HIV positive indi-
viduals were thinner and more frequent smokers. In the
group of individuals above the age of 75 HIV negative
had the same prevalence of smoke habits as HIV-
positive ones (10.84% vs 15.23%, p = 0.39) (Table 1).
With regards to HIV variables mean HIV duration of
17 years. However, 33% of them had HIV exposure for
more than 20 years, representing people aging with HIV
from the pre-ART era. The age at HIV diagnosis was sig-
nificantly higher (60.3 ± 7.6 vs 52.1 ± 8.2) in “old” individ-
uals compared to “youngest old” HIV people (p < 0.01).
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HIV positive patients had well recovered immune status,
as assessed with a mean CD4/CD8 equal to 0.97 and
reached HIV-RNA viral load below 40 copies/mL in 94%.
Hepatitis C and B co-infection were 13% and 10% respect-
ively (Table 1).
NCDs, MM and PP prevalence increased with age cat-
egories with the exception of T2DM and dyslipidaemia
in HIV negative patients only (Table 2).
The overall prevalence of MM and PP respectively
amounted to 64% and 37% in HIV-positive patients, and
59% and 24% in controls.
In “youngest old” group CKD, DLM and PP only
were more prevalent in HIV positive patients; the
same was true in the “old” group for T2DM, DLM
and CKD (Table 2).
When the HIV-positive group was stratified by dur-
ation of HIV infection, individual comorbidities were
significantly more frequent in the HIV-positive sub-
groups with HIV exposure> 10 years when compared to
HIV negative, except for HTN and CVD. The prevalence
of COPD was higher in the controls (fig. 1).
Probability of MM was higher in HIV positive pa-
tients aging with HIV for more than 10 years when
compared to HIV negative controls (fig. 2a). Independent
predictors for MM were age > 75 years, higher BMI, male
gender and HIV duration above 20 years, all p < 0.01
Table 1 Demographic, anthropometric and HIV variables in the GEPPO cohort
Total n = 1573 HIV-negative vs HIV-positive HIV-negative HIV-positive
HIV-
(n = 315, 20·03%)
HIV+
(n = 1258, 79·97%)
p 65–74 years
(n = 224, 71·11%)
≥ 75 years
(n = 91, 28·89%)
p 65–74 years
(n = 965, 76·71%)
≥ 75 years
(n = 293, 23·29%)
p
Variable Mean (SD)
[sample size]
Mean (SD/%) [sample size] Mean (SD/%) [sample size] Mean (SD/%) [sample size]
Gender (F) 271 (17.23%)
[1573]
66 (20.95%)
[315]
205 (16.3%)
[1258]
0.06 * 42 (18.75%)
[224]
24 (26.37%)
[91]
0·18 * 155 (16.06%)
[965]
50 (15.06%)
[293]
0.75 *
Female Age 71.23 (3.94)
[271]
71.55 (3.42)
[66]
71.15 (4.05)
[205]
0.12 *** 69.83 (2.48)
[182]
77.46 (2.08)
[67]
< 0.01*** 69.46 (2.52)
[810]
77.5 (2.0)
[243]
< 0.01***
Male Age 71.71 (4.27)
[1302]
72.61 (4.37)
[249]
71.42 (4.21)
[1053]
0.06 *** 70.05 (2.75)
[42]
75.61 (0.49)
[25]
< 0.01*** 69.35 (2.48)
[155]
77.17 (1.)
[50]
< 0.01***
BMI 26.55 (8.59)
[1224]
28.65 (4.18)
[301]
25.87 (9.5)
[923]
< 0.01 *** 28.71 (4.04)
[8]
28.52 (4.54) [6] 0.65 *** 26.15 (10.66)
[264]
24.98 (3.95)
[71]
0.04 ***
Current smoker 313 (23.29%)
[1344]
42 (14.24%)
[295]
271 (25.83%)
[1049]
< 0.01* 33 (15.57%)
[212]
9 (10.84%) [83] 0.39 * 234 (29.03%)
[806]
37 (15.23%)
[243]
< 0.01*
HIV duration
(years)
NA NA 17.17 (7.65)
[1240]
NA NA NA NA 17.24 (7.76)
[949]
16.92 (7.3)
[291]
0·64 **
< 10 years NA NA 263 (21.23%)
[1240]
NA NA NA NA 200 (21·07%)
[949]
63 (21.72%)
[291]
0·9*
10–20 years NA NA 561 (45.28%)
[1240]
NA NA NA NA 433 (45.63%)
[949]
128 (44.14%)
[291]
> 20 years NA NA 415
(33.49%)
[1240]
NA NA NA NA 316 (33.3%)
[949]
99 (34.14%)
[291]
CD4 nadir NA NA 197.5 (84–310)
[1240]
NA NA NA NA 200 (89.75–308)
[949]
191 (74.75–320)
[291]
0·61 **
Current CD4 NA NA 644.58 (1240)
[1258]
NA NA NA NA 651.23 (290.95)
[949]
622.55 (282)
[291]
0·18 **
CD4/CD8 NA NA 0.97 (1.45)
[1240]
NA NA NA NA 0.92 (0.8)
[949]
1.13 (2.63)
[291]
0·28 ***
Viral load ≤40 NA NA 1044 (94.31%)
[1107]
NA NA NA NA 812 (94.97%)
[855]
232 (92.06%)
[252]
0.11 *
Viral load
undetectable
NA NA 925 (86.53%)
[1068]
NA NA NA NA 712 (86.72%)
[821]
213 (85.89%)
[248]
0.82 *
HBV co-infection NAv NAv 103 (9.83%)
[1048]
NAv NAv NAv NAv 84 (10.51%)
[799]
19 (7.63%)
[249]
0·23*
HCV co-infection NAv NAv 141 (12.57%)
[1121]
NAv NAv NAv NAv 113 (13·11%)
[862]
28 (10·77%)
[259]
0·12 *
Age at HIV
diagnosis
NA NA 54·03 (8.83)
[1239]
NA NA NA NA 52·11 (8.28)
[949]
60·3 (7.6)
[290]
< 0·01***
Triple/M ART NA NA 390 (31.91%)
[1222]
NA NA NA NA 312 (31.01%)
[1006]
78 (36.11%)
[216]
0·17 *
Mono/dual
ART
NA NA 832 (68.09%)
[1221]
NA NA NA NA 694 (68.99%)
[1006]
138 (63.89%)
[215]
Abbreviations: ART: AntiRetroviral Therapy; BMI: Body Mass Index; HIV: Human Immunodeficiency Virus; NA: not applicable. NAv: not available;
p value legends: * X2 test; ** Wilcoxon; *** t test
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(fig. 2b). A second model restricted to HIV patients
only (data not presented in fig. 2), while confirming
the same predictors of the previous model, failed to
identify any association between traditional HIV variables
and MM. In particular: current CD4/CD8 OR = 1.53
(95% CI:0.97–2.43, p = 0.07), CD4 nadir OR = 1 (95% CI:
1–1, p = 0.83), HIV RNA undetectability OR = 1.37
(95% CI:0.65–3.04, p = 0.42) and residual ARV exposure
duration OR = 0.97 (95% CI:0.9–1.05, p = 0.45).
We examined in the GEPPO cohort the six most
frequently prescribed drug classes for the treatment
of NCDs. There was no difference in the prescription
of and antidepressants or acetylsalicylic acid (ASA),
ace-inhibitors (ACE) and beta-blockers, commonly
used in primary or secondary cardiovascular disease
prevention. A higher prescription of benzodiazepines
(BDZ), used as sleep inducers, was present in HIV
negative people (p < 0.01), while a higher prescription
of statins for dyslipidaemia in HIV positive patients
was observed (p < 0.01) (fig. 3a). PP was higher in
HIV positives, irrespective of duration of HIV-infection
(Fig. 3b).
At any age PP was more common in HIV patients
(fig. 4a). Drivers for higher PP risk were HIV duration
Table 2 NCDs prevalence comparing “youngest old” and “old” individuals
65–74 Years Old ≥ 75 Years Old
HIV- (n = 224, 18.84%) HIV+ (n = 965, 81.16%) p HIV- (n = 91, 23.7%) HIV+ (n = 293, 76.3%) p
Variable Frequency [sample size] Frequency [sample size]
HTN 149 (66.52%) [224] 396 (60.83%) [652] 0.15 61 (67.03%) [91] 155 (71.76%) [216] 0.49
T2DM 50 (22.32%) [224] 176 (27.54%) [629] 0.15 14 (15.38%) [91] 65 (31.25%) [208] < 0.01
CVD 41 (18.3%) [224] 106 (16.88%) [628] 0.70 28 (30.77%) [91] 58 (29.15%) [199] 0.88
CKD 5 (5%) [100] 115 (17.06%) [674] < 0.01 4 (10%) [40] 56 (25.93%) [216] 0.04
COPD 20 (9.13%) [219] 41 (6.61%) [620] 0.28 17 (18.89%) [90] 19 (9.79%) [194] 0.05
DLM 59 (57.84%) [102] 462 (70%) [630] 0.02 20 (50%) [40] 156 (74.64%) [209] < 0.01
MM 57 (57.58%) [99] 371 (61.32%) [605] 0.55 25 (62.5%) [40] 139 (73.94%) [188] 0.20
PP 44 (19.64%) [224] 169 (35.28%) [479] < 0.01 32 (35.16%) [91] 73 (42.94%) [170] 0.27
Abbreviations: HTN: Hypertension; T2DM: type 2 diabetes mellitus; CVD: Cardiovascular Disease; CKD: Chronic Kidney Disease; COPD: Chronic Obstructive Pulmonary
Disease; DLM: Dyslipidaemia; MM: Multimorbidity; PP - Polypharmacy
Fig. 1 Prevalence of NCDs in the cohort as a whole, and in three HIV duration groups (< 10, 10–20 and > 20 years). NCDs prevalence (%) and
absolute numbers (n) are indicated for HIV negative and HIV positive with different HIV duration groups. Indicated p-value refers to HIV-positive
versus HIV-negative comparison. Abbreviations DLM: Dyslipidaemia; COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic Kidney Disease;
CVD: Cardiovascular Disease; T2DM: Type 2 Diabetes mellitus.HTN: Hypertension
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with progressive OR increase per increment of HIV
duration category and age above 75 years (fig. 4b).
A second model restricted to HIV patients only (data
non-presented in fig. 4), while confirming the same
predictors of the previous model, failed to identify
any association between traditional HIV variables and
PP. In particular: current CD4/CD8 OR = 0.83 (95%
CI:0.44–1.52, p = 0.54), CD4 nadir OR = 1 (95% CI:1–1,
p = 0.73), HIV RNA undetectability OR = 1.75 (95% CI:
0.91–3.48, p = 0.1) and residual ARV exposure duration
OR = 1.03 (95% CI:0.93–1.13, p = 0.61). Significant predic-
tors identified in the original model were confirmed.
Discussion
Our findings indicate that MM and PP in HIV-positive
individuals are both related to longer duration of HIV-
infection rather than older age per se.
People aging with HIV for more than 20 years are
almost three times as likely to have MM than those
infected for a shorter period.
a b
Fig. 2 a Probability of MM per year above the age of 65. The HIV positive patients are stratified by duration of HIV infection (< 10, 10–20 and >
20 years). b Multivariable logistic regression models to detect the independent predictors of MM. Abbreviations – MM: Multimorbidity
Fig. 3 a Prevalence of the six drug classes most frequently prescribed for the treatment of NCdD and b prevalence of PP in HIV negative and HIV
positive stratified by duration of HIV infection (< 10, 10–20 and > 20 years). Drug classes prevalence (%) and absolute numbers (n) are indicated
for HIV negative and HIV positive with different HIV duration groups. Indicated p-value refers to HIV-positive versus HIV-negative comparison.
Abbreviations – ASA: acetylsalicylic acid; AntiDepres: antidepressants; BZD: benzodiazepines; ACE; Angiotensin Converting Enzyme inhibitors;
BBlock: beta-adrenergic blocking agents; Statine: statins
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It can be noticed that HIV positive patients belonging
to the GEPPO cohort who have been living with HIV for
more than 20 years were all exposed to the first gener-
ation of ART. These are “silver champions”, since they
represent the best survivors of their generation and
warrant as much attention as geriatric medicine has paid
to centenarians, possibly identifying protective factors
for NCDs.
These individuals have been exposed for years to de-
tectable VL in the pre-ART era and have received highly
toxic ART, both of them representing a permanent risk
of NCDs.
However, it must be acknowledged that this phenomenon
may change in future years. The START trial, a large ran-
domized clinical trial conducted in 35 countries enrolling
over 4500 HIV+ ART-naïve subjects randomized to imme-
diate (CD4 ≥ 500/μL) or deferred ART initiation (CD4 <
350/μL) demonstrated that immediate ART reduced inci-
dence of NCDs, pointing to the role of long-term immune
activation and inflammation. In the contemporary setting
of immediate access to new-generation ART, it can be
hypothesised that the prevalence of NCDs and MM will be
reduced in the years to come [23].
The prevalence of comorbidities was different in the
HIV-positive patients and controls. The higher preva-
lence of DLM, CKD and T2DM has been widely de-
scribed [12], and can at least partially be attributed to
the metabolic toxicities of ART [24–26]. COPD was
more prevalent in the HIV-negative individuals. This is
somewhat surprising considering the higher proportion
of smokers among HIV positive patients (26% vs 14%),
and it suggests that infectious diseases physicians are
less likely to use spirometry to screen HIV positive pa-
tients. The European AIDS Clinical Society (EACS)
guidelines have only recently introduced COPD as a co-
morbid condition that should be screened for [21].
There was no difference in the prevalence of CVD or
HTN as has been observed in other cohorts [27], pos-
sibly due to strategies used to reduce CV risk factors,
the increasing use of lipid-friendly ART agents, and re-
duction of immunodeficiency state.
Most of the participants of the GEPPO cohort have
MM (59%), this appears to be the norm in HIV-infected
geriatric patients [9]. We still need research to investi-
gate the multifactorial nature of MM and the impact of
this condition on quality of life, functional status impair-
ment, health service use, and mortality. This will help
healthcare services to address the unmet needs of
PLWH with MM.
HIV, proportionally with its duration is a risk factor
for PP. HIV positive patients have been visiting physi-
cians since a young age and PP may be the result of the
“medicalisation” of early diagnosis of NCDs.
MM and PP were both more prevalent in the HIV-
positive group, respectively 64% and 37%. The increased
burden of PP in this HIV cohort is striking, particularly
in the light our very restrictive definition of PP (the
chronic use of five or more drugs, excluding ART). The
greater the number of medicines patient takes, the
greater the risk of adverse effects, and the greater the
risk of drug–drug interactions, leading to poor health
outcomes, hospitalisations and mortality [28]. This is a
dilemma for prescribers, who try to keep the number of
medicines to a minimum while ensuring that patients re-
ceive what evidence-based guidelines advocate as being
in their best interest [29].
Apparently, ID physicians and geriatricians use differ-
ent drugs to treat the same comorbidities. An important
Fig. 4 a Probability of PP per year above the age of 65. The HIV positive patients are stratified by duration of HIV infection (< 10, 10–20 and >
20 years). b Multivariable logistic regression models to detect the independent predictors of PP.Abbreviations – PP: polypharmacy
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difference regards the use of statins. Studies have under-
lined the need to increase statin prescription in HIV-
positive patients due to increased cardiovascular risk.
However, the use of statins in the elderly is a concern in
the context of sarcopenia and fall risk [30]. Possibly geri-
atricians more than ID physicians are more concerned
of this issue and this may be reflected by the fewer statin
prescriptions received by the HIV negative controls in
the GEPPO cohort.
Benzodiazepines were prescribed more frequently in the
HIV negative than for the HIV positive patients. This may
reflect the aversion of former intravenous drug users to
use psychoactive drugs that may induce dependence.
With regard to gender, the prevalence and risk of MM
(but not PP) was higher among males.
As expected males had increased risk of comorbidities
but this was not the same for PP in the Italian national
health system context were drugs for NCDs are provided
for free in geriatric patients. The risks of MM and PP
were different in the subjects aged more or less than
75 years. Apparently, the “younger-old” and “old” geriat-
ric categories cover two subsets of elderly people with
different risk profiles, and this must also be considered
in HIV-positive patients.
Our data claim for a tailored approach to NCDs, and
highlight the development of drug de-prescription strat-
egies in the management of PP. Although de-prescribing
is relatively new in HIV medicine, the use of the Beers
criteria [31], IPET (Improving Prescribing in the Elderly
Tool) [32] and STOPP-START criteria [33, 34] to adjust
therapy and reduce potentially inappropriate drugs is
well established in geriatric practice, and should be ex-
tended to the HIV setting [35].The benefit of de-
prescribing in HIV positive geriatric patients has never
been evaluated so far.
The GEPPO cohort includes HIV-positive patients aged
≥65 attending ten HIV clinics across Italy (who, taken
together, makes a quite significant absolute number of
elderly people living with HIV) and a group of age and
gender-matched HIV-negative controls attending a single
geriatric clinic. People of this age frequently visit geriatric
clinics because of age-related comorbidities. Therefore,
our cohort provides a new opportunity to compare HIV-
infected patients with HIV-negative controls better repre-
sentative of the general population than subjects attending
centres for sexually transmitted diseases or intravenous
drug user facilities used in previous studies.
This study has a number of limitations. Some of these are
intrinsic to cross-sectional nature of observational studies,
which cannot reveal any causative association between vari-
ables. The prevalence of comorbidities, although standard-
ized in cohort studies may overestimate disease condition.
This is the case of DLM, where use of statins is used as
diagnostic criteria. We found no significant difference of
HIV-related variables other than the duration of HIV infec-
tion to be associated with the risk of MM or PP. For this
reason, ART exposure was not considered as a covariate,
also because it requires properly designed clinically study.
Cumulative smoke pack year was not addressed, because
not routinely collected in all the clinics. A major limitation
of this study was the lack of information on geriatric
syndrome, including frailty and falls. Geriatric syndromes,
better than NCDs capture the healthy aging outcome that
all geriatric studies should address (ref). This information
will be available in future studies of GEPPO cohort.
To the best of our knowledge, the GEPPO is the first
geriatric cohort of HIV-positive patients that may contrib-
ute to identify unmet clinical and research needs in terms
of comorbidities and their implications for PP. This model
highlights the need for evidence-based screening and
monitoring protocols to ensure high-quality care.
Conclusions
The findings of this study show MM and PP burden in
geriatric HIV positive patients are related to longer dur-
ation of HIV-infection rather than older age per se.
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